HCM
NTLA icon

Hollencrest Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Hollencrest Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,828
Closed -$49.1K – 1325
2026
Q1 		$49.1K Buy
+3,828
New +$48.8K ﹤0.01% 555
2025
Q1 		– Sell
-29
Closed -$338 – 1205
2024
Q4 		$338 Hold
29
– – ﹤0.01% 1114
2024
Q3 		$596 Hold
29
– – ﹤0.01% 1039
2024
Q2 		$649 Hold
29
– – ﹤0.01% 1004
2024
Q1 		$798 Hold
29
– – ﹤0.01% 976
2023
Q4 		$884 Hold
29
– – ﹤0.01% 950
2023
Q3 		$917 Hold
29
– – ﹤0.01% 976
2023
Q2 		$1.18K Hold
29
– – ﹤0.01% 1011
2023
Q1 		$1.08K Hold
29
– – ﹤0.01% 1012
2022
Q4 		$1.01K Buy
+29
New +$1.38K ﹤0.01% 1008

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Hollencrest Capital Management's NTLA Position: Q2 2026 in Review

Hollencrest Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 3,828 shares — an estimated $49.1K sold.

Hollencrest Capital Management first reported a position in NTLA in Q4 2022 and held it in 10 quarters. The position peaked at $49.1K in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Hollencrest Capital Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hollencrest Capital Management sold 3,828 Intellia Therapeutics shares in Q2 2026, an estimated $49.1K.
  • Hollencrest Capital Management first reported a position in Intellia Therapeutics in Q4 2022 and held it in 10 quarters.
  • Hollencrest Capital Management's Intellia Therapeutics position peaked at $49.1K in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.